Denys, Hannelore
Martinez-Mena, Corina L.
Martens, Marc T.
D’Hondt, Randal G.
Graas, Marie-Pascale L.
Evron, Ella
Fried, Georgeta
Ben-Baruch, Noa E.
Vulsteke, Christof
Van Steenberghe, Mona M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
https://doi.org/10.1007/s10549-020-05604-7
Funding for this research was provided by:
F. Hoffmann-La Roche
Article History
Received: 20 November 2019
Accepted: 18 March 2020
First Online: 2 April 2020
Compliance with ethical standards
:
: The institution of Dr Denys received travel grants of Pfizer, Roche, PharmaMar, Teva, AstraZeneca, speakers fee or honoraria for participation in Advisory Boards of Pfizer, Roche, PharmaMar, AstraZeneca, Eli Lilly, Novartis, Amgen, Tesaro, Bristol-Myers Squibb and research funds of Roche. Dr Evron received financial support from Roche for attending symposia. Dr Martinez-Mena received travel grants from Roche. Dr Van Steenberghe is employee of Roche Belgium NV/SA.
: The study was conducted in accordance with the principles of the “Declaration of Helsinki” and compliant with the International Conference on Harmonisation (ICH) guidelines for good clinical practice (GCP) standards as well as with all local or national laws and regulations concerning clinical studies. The protocol was approved by the appropriate ethics committees. Patients gave written informed consent before being included in the study.